| __timestamp | MiMedx Group, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 14993000000 |
| Thursday, January 1, 2015 | 133384000 | 14247000000 |
| Friday, January 1, 2016 | 179997000 | 14192000000 |
| Sunday, January 1, 2017 | 220119000 | 14997000000 |
| Monday, January 1, 2018 | 258528000 | 16471000000 |
| Tuesday, January 1, 2019 | 198205000 | 14369000000 |
| Wednesday, January 1, 2020 | 181022000 | 14197000000 |
| Friday, January 1, 2021 | 198359000 | 14886000000 |
| Saturday, January 1, 2022 | 208789000 | 14253000000 |
| Sunday, January 1, 2023 | 211124000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
Cracking the code
In the competitive world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Novartis AG and MiMedx Group, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Novartis AG consistently maintained high SG&A expenses, peaking at approximately $16.5 billion in 2018. Despite this, their expenses showed a downward trend, decreasing by about 17% by 2023. In contrast, MiMedx Group, Inc. saw a steady increase in SG&A expenses, rising by 133% from 2014 to 2023. This divergence highlights Novartis's strategic cost management, while MiMedx's growth phase reflects its investment in expansion. Understanding these trends offers valuable insights into how industry giants and emerging players navigate financial strategies in a dynamic market.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Novartis AG and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Novartis AG and BioCryst Pharmaceuticals, Inc.
BeiGene, Ltd. and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Perrigo Company plc or MiMedx Group, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Vericel Corporation vs MiMedx Group, Inc. Trends and Insights